Meglumine antimoniate

From WikiProjectMed
Jump to navigation Jump to search
Meglumine antimoniate
Other namesMeglumine antimonate
  • Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
Clinical data
Defined daily dosenot established[1]
External links
AHFS/Drugs.comMicromedex Detailed Consumer Information
Chemical and physical data
Molar massVariable
3D model (JSmol)
  • O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO
  • InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 checkY

Meglumine antimoniate is a medicine used to treat leishmaniasis.[2] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[2] It is given by injection into a muscle or into the area infected.[2]

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.[2] It should not be used in people with significant heart, liver, or kidney problems.[2] It is not recommended during breastfeeding.[2] It belongs to a group of medications known as the pentavalent antimonials.[2]

Meglumine antimoniate came into medical use in 1946.[3] It is on the World Health Organization's List of Essential Medicines.[4] The wholesale cost in the developing world is about 4.32 USD per vial as of 2014.[5] It is available in Southern Europe and Latin America but not the United States.[6][7]

Medical uses


The defined daily dose is not established.[1]

Society and culture

It is manufactured by Aventis[8] and sold as Glucantime in France, and Glucantim in Italy.

See also


  1. 1.0 1.1 "WHOCC - ATC/DDD Index". Archived from the original on 1 July 2021. Retrieved 21 September 2020.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 183. hdl:10665/44053. ISBN 9789241547659.
  3. Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20.
  4. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. "Meglumine Antimonate". International Drug Price Indicator Guide. Archived from the original on 22 January 2018. Retrieved 8 December 2016.
  6. Bope, Edward T.; Kellerman, Rick D.; Rakel, Robert E. (2010). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 143773572X. Archived from the original on 2016-12-20.
  7. Gorbach, Sherwood L.; Bartlett, John G.; Blacklow, Neil R. (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20.
  8. Aventis press release Archived 2014-05-22 at the Wayback Machine, 15 April 2005. (in German)

External links